Drug intelligence / Profile preview

BAY 11-7082

Development stage
Preclinical
Lead developer
Bayer Pharmaceuticals
Modality
Small Molecules
Administration
Intraperitoneal (in Animal Models), In Vitro Research Use
01

Overview

BAY 11-7082 is a synthetic, cell-permeable small molecule primarily known as an irreversible inhibitor of the **NF-κB pathway** and the **NLRP3 inflammasome**. It inhibits phosphorylation of IκB-α by interfering with IκB kinase activity, thereby preventing NF-κB translocation to the nucleus and subsequent transcriptional activation of pro-inflammatory genes[1][4][7]. BAY 11-7082 also directly inhibits the ATPase activity of NLRP3, blocking inflammasome activation, and functions as an active site-directed irreversible inhibitor of protein tyrosine phosphatases (PTPs)[1][4][7]. Additional described activities include blocking IRF3, STAT1, ERK, p38, and JAK2 signaling[1]. Research suggests potential utility for **anti-inflammatory**, **anti-cancer**, and **neuroprotective** purposes in preclinical models, including mouse models of autoimmune encephalomyelitis and various cancer lines[1][3][6]. BAY 11-7082 is not approved for clinical use and is primarily used as a research tool compound[6].

Brand names
BAY 11-7082BAY11-7082BAY-11-7082
Other names
BAY 11-7082BAY11-7082BAY-11-708219542-67-7
02

Targets

LUBAC (Linear Ubiquitin Chain Assembly Complex)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)UBE2N (Ubiquitin-conjugating enzyme E2 N)E2F1 (E2F Transcription Factor 1)MAPK3 (Mitogen-activated protein kinase 1)IRF3 (Interferon regulatory factor 3)JAK2 (Janus kinase 2)NF-κBPTPN1 (Protein tyrosine phosphatase 1B)STAT1 (Signal transducer and activator of transcription protein 1)MAPK14 (p38 mitogen-activated protein kinase alpha)

Beyond the preview

Go deeper on BAY 11-7082.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAY 11-7082.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call